Vaxcyte (PCVX) Accumulated Depreciation (2019 - 2023)

Vaxcyte (PCVX) has 5 years of Accumulated Depreciation data on file, last reported at $9.3 million in Q4 2023.

• Accumulated Depreciation for Q4 2023 came in at $9.3 million, up 51.58% year-over-year; the trailing twelve-month figure through Dec 2023 was $9.3 million (up 51.58% YoY), and the FY2023 annual result was $9.3 million, up 51.58% from the prior year.
• Accumulated Depreciation rose to $9.3 million in Q4 2023 per PCVX's latest filing, from $8.4 million in the prior quarter.
• Over five years, Accumulated Depreciation peaked at $9.3 million in Q4 2023 and troughed at $3.0 million in Q4 2019.
• A 5-year average of $5.3 million and a median of $4.8 million in 2021 frame the typical range for Accumulated Depreciation.
• The sharpest annual moves came in 2021 and 2022: Accumulated Depreciation slipped 13.4% in 2021, then soared 72.41% in 2022.
• A 5-year view of Accumulated Depreciation shows it stood at $3.0 million in 2019, then jumped by 37.39% to $4.1 million in 2020, then decreased by 13.4% to $3.5 million in 2021, then surged by 72.41% to $6.1 million in 2022, then surged by 51.58% to $9.3 million in 2023.
• Business Quant data shows PCVX's Accumulated Depreciation at $9.3 million in Q4 2023, $8.4 million in Q3 2023, and $7.6 million in Q2 2023.